Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine With or Without Epoetin Alfa in Low-Risk Myelodysplastic Syndromes
NCT00003681Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 1998
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of amifostine in myelodysplastic syndrome (MDS) (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Partial or Complete Response Rate, Duration of Response and 2 more. Status: unknown.
02
Drugs
amifostine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003681.